Ozempic and Wegovy Ileus and Bowel Obstruction Claims

The current prescribing information for Ozempic and Wegovy lists ileus, intestinal obstruction, and severe constipation, including fecal impaction, among gastrointestinal reactions reported after approval. Those reports can be important to a safety review, but they do not establish how often an event occurs or prove that semaglutide caused an individual patient’s condition. Logue Law Group handles Ozempic and Wegovy injury matters and works with leading national mass-tort firms to review potential claims. Every matter depends on its own medical and legal evidence. A potential Ozempic bowel obstruction claim requires case-specific evidence; a postmarketing report alone does not establish causation.

Ileus, intestinal obstruction, and severe constipation

Ileus is a disruption or slowing of normal intestinal movement. A mechanical bowel obstruction involves a physical blockage. Severe constipation and fecal impaction are related but distinct diagnoses. Symptoms can overlap, and only a qualified clinician can diagnose the condition and determine appropriate treatment.

Possible symptoms may include significant abdominal pain or swelling, nausea, vomiting, inability to pass stool or gas, or worsening constipation. These symptoms can have many causes. Sudden or severe abdominal symptoms, persistent vomiting, or inability to pass stool or gas need prompt medical attention. Do not rely on this page to diagnose a condition or change a prescription; follow your healthcare professional’s instructions.

What FDA labeling says about semaglutide

FDA-approved labeling for both Ozempic and Wegovy reports ileus, intestinal obstruction, and severe constipation including fecal impaction during postmarketing use. The labels explain that voluntary reports come from a population of uncertain size, so frequency cannot reliably be estimated and a causal relationship to drug exposure cannot always be established. The label is a source for reviewing the safety information available for a product; it is not proof of what caused a particular person’s injury.

Products containing semaglutide have different indications, formulations, and dosing. A careful review identifies the exact product used, whether it was an injection or tablet, the dose and escalation schedule, the treatment dates, the diagnosis, and other relevant medicines and health conditions. A clinician must assess possible causes and contributing factors.

How Ozempic bowel obstruction claims are assessed

A person diagnosed with ileus, bowel obstruction, severe constipation, or fecal impaction during or after Ozempic or Wegovy use may ask whether the circumstances warrant legal review. A diagnosis or FDA postmarketing entry does not automatically create a product-liability claim. A legal analysis may consider warnings in effect at the time, the medical timeline, the product and dose, alternative causes, the severity and duration of harm, and the law that applies.

• Medical records, imaging, procedures, hospital admissions, and discharge instructions
• Prescription and pharmacy records identifying the specific semaglutide product, dose, and dates
• Symptoms, treatment notes, bowel-history details, and relevant prior conditions
• Other medicines and possible medical or surgical causes of the condition
• Follow-up care, lasting effects, expenses, lost income, and daily impact
• Applicable filing deadlines and procedural requirements

Keeping a timeline and copies of records can help organize a review. Do not send confidential medical records through an unsecured channel; ask the firm how to provide information safely. A consultation does not guarantee acceptance, filing, or success of a claim.

Related Ozempic and Wegovy injury information

Read the Ozempic and Wegovy injury overview and our pages about gastroparesis and severe stomach-emptying problems, pancreatitis, and kidney injury. Each condition requires a separate medical and legal assessment.

Request an individual case review

Logue Law Group handles Ozempic and Wegovy injury matters and works with leading national mass-tort firms on complex pharmaceutical litigation. Potential matters are reviewed individually. No result, settlement, or eligibility determination is promised. Contacting the firm does not create an attorney-client relationship; representation begins only after conflicts are checked and a written agreement is signed. Call (412) 387-6901 or contact us online.

Medical information and legal advertising notice: This page provides general information, not medical advice or a conclusion that a medicine caused anyone’s condition. Seek care from a qualified healthcare professional. Laws and deadlines vary. Prior results do not guarantee a similar outcome.

Sources: Current Ozempic prescribing information (DailyMed); Current Wegovy prescribing information (DailyMed).